immortal time bias are certainly needed for future studies studying the correlation between toxic effects and treatment response.

Douglas B. Johnson, MD, MSCI
Fei Ye, PhD
Anna K. Dewan, MD

Author Affiliations: Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (Johnson); Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee (Ye); Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee (Dewan).

Corresponding Author: Douglas B. Johnson, MD, MSCI, Department of Medicine, Vanderbilt University Medical Center, 777 PRB, 2220 Pierce Ave, Nashville, TN 37232 (douglas.b.johnson@vumc.org).

Published Online: September 26, 2019. doi:10.1001/jamaoncol.2019.3817

Conflict of Interest Disclosures: Dr Johnson serves on advisory boards for Array Biopharma, Bristol-Myers Squibb, Incyte, Merck, and Novartis; has received research support from Bristol-Myers Squibb and Incyte; and has received travel support from Genentech. No other disclosures were reported.

Funding/Support: Dr Johnson received funding from the National Institutes of Health (K23 CA204726 and R01CA227481) and the James C. Bradford Jr Melanoma Fund.

Role of the Funder/Sponsor: The funders generally supported time and effort for design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation/review of the manuscript. They had no role in approval of or decision to submit the manuscript for publication.


CORRECTION

Errors in Statistical Programming: In the article titled “Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer,” published online February 2, 2017, and also in the September 2017 issue of JAMA Oncology, an error occurred in the statistical programming of the analysis. All analyses were recalculated, which resulted in changes to the population-attributable risk proportion estimates for some of the risk factors and combinations of risk factors, most of which did not alter the conclusions. This article was corrected online.


Error in Author’s Name: In the article titled “Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial,” published online September 5, 2019, the wrong initial was used for Dr Harding’s middle name. Dr Harding’s correct name is James J. Harding, MD. This article has been corrected online.


Error in the Figure: In the Clinical Challenge titled, “Erosive Deforming Inflammatory Arthritis in a Patient With Cervical Adenocarcinoma,” which published online September 26, 2019, the arrowheads were missing from the Figure panels. This article was corrected online.


Status Change to Open Access After Publication: The Original Investigation titled “Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial,” published online September 12, 2019, has changed status since publication. It is now open access under the CC-BY-NC-ND license. This article was corrected online.


Missing eTable: In the Original Investigation titled “Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer: A Phase Ib/2 Pilot Clinical Trial,” published in JAMA Oncology online first on October 3, 2019, eTable 3 was missing from Supplement 2. It has been added to Supplement 2 and cited in the Results. This article was corrected online.